Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological, oncological, and inflammatory diseases with unmet medical needs. The company advances its pipeline through a reSEARCH and DEVELOPMENT model, offering products including Naldebain (LT1001), a long-acting analgesic injection for postoperative pain relief that has received marketing approvals in Taiwan, Singapore, Thailand, Malaysia, and Ukraine; LT3001, a neuroprotectant in Phase II clinical trials for acute ischemic stroke; LT5001, which has completed Phase I trials for uremic pruritus; LT6001 in preclinical development for neurological disorders; and LT2003 in preclinical stages for oncology indications. Lumosa Therapeutics Co., Ltd. also engages in technology investment, consulting, service, and transfer activities. Incorporated in 2000 and headquartered in Taipei, Taiwan, the company operates primarily in Taiwan, Asia, the Americas, and Europe, targeting patients with central nervous system disorders, cancer, and inflammatory conditions. Recent developments include a global exclusive license agreement signed in April 2025 with the University of North Carolina at Chapel Hill for patented T-cell enhancement technology to bolster regenerative medicine and next-generation CAR-T therapies for solid tumors and other indications; expansion of LT3001 Phase II trials into multiple European Union countries announced in January 2024; and conclusion of LT3001 Phase II trials ahead of schedule in March 2025.